SUMMARY Thirty-eight patients with rheumatoid arthritis in remission on penicillamine were entered into a prospective, randomised, placebo controlled study to determine the effects of gradual penicillamine withdrawal, to find a serological marker capable of predicting relapse, and to assess the effects of reintroduction of penicillamine. 80% of patients attempting gradual penicillamine withdrawal flared. There was no single serological marker capable of predicting outcome consistently. Decreasing SH levels were highly specific for recurrence of active synovitis but were insensitive. Reintroduction of penicillamine was successful. The implications of these findings, particularly concerning duration of therapy with disease modifying drugs, are discussed.
The efficacy of D-penicillamine (penicillamine) in rheumatoid arthritis (RA) has been demonstrated in many double-blind prospective studies.1`4 However, complete remission for at least 2 years, defined by no joint symptoms, normal laboratory tests, and withdrawal of all drugs, occurs in only 4% of patients on penicillamine.5 Advice given to patients with RA who have a sustained remission on penicillamine is conflicting. Do such patients attempt to reduce their dose of penicillamine gradually or to continue treatment indefinitely? Indeed, is the maintenance of the remission due to the action of the drug itself or to the natural history of rheumatoid arthritis?
Many rheumatologists feel that, as the incidence of side effects such as thrombocytopenia6 and proteinuria7 is greater on higher doses of penicillamine, gradual reduction of the dose of the drug should be attempted. Anecdotal evidence suggests that on withdrawing penicillamine a recurrence of inflammatory activity is likely and that reintroduction of the drug is less successful. 8 9 There have been no published trials assessing the effects and risks of gradual penicillamine withdrawal. We therefore designed a prospective, randomised, placebo controlled study. Our 
remained in remission 9 to 12 months after complete withdrawal (Fig. 1) . Ten of the 15 patients who flared developed polyarticular synovitis, while only five had a relapse affecting only one joint.
The results were analysed to determine whether or not any serological markers predicted relapse. For this purpose the 2 patients who flared despite continuation of penicillamine and the 4 patients in remission after penicillamine withdrawal were excluded, as it was thought that these patients were unlikely to demonstrate that marker. In determining the sensitivity and specificity of these possible markers all 38 patients were analysed. In the withdrawal group there was no significant change in haemoglobin, platelet count, plasma viscosity, immunoglobulin levels, or rheumatoid factor at or prior to the time of relapse. The Clq BA was normal in both groups of patients and remained normal throughout the study, even at the time of relapse in the withdrawal group. The mean CRP level increased in the withdrawal group (Fig. 2) required an increased dose but eventually responded to the higher dose. However, 6 months after relapse the CRP had not returned to normal in 5 patients.
Discussion
The patients chosen for the study were a selected group of patients with RA who were in remission on penicillamine, with no toxicity. They were, by selection, a group with severe RA who had done well on penicillamine. This study was designed with 3 specific goals.
Firstly, we have shown that 80% of our patients in remission attempting gradual penicillamine withdrawal flared. As the temporal relationship between withdrawal and recurrence of active synovitis was so strong (the probability of this occurring by chance alone was 4-73 x 1 0-, exact probability test) penicillamine withdrawal can be implicated in the cause of the recurrence. This suggests that penicillamine continues to suppress disease activity many years after successful induction of remission and that prolonged spontaneous remission occurs infrequently in this group of patients with RA. However, 4 patients remain in remission after complete withdrawal of penicillamine and presumably represent examples of spontaneous remission. This sustained benefit from penicillamine is similar to the experience obtained with gold therapy, where prolonged maintenance treatment is advisable."5-17
Secondly, we found no single serological marker that predicted outcome consistently, The serum SH levels were the best guide to predicting a clinical relapse but were too insensitive to be of routine clinical assistance. The SH levels are not an indirect assay of blood D-penicillamine levels, as the SH levels remained normal in the 4 patients who withdrew penicillamine therapy completely but remained in remission. Also the plasma concentration of D-penicillamine is generally less than 10 jig/ml (approximately 5 x 10-' mol/l) in rheumatoid patients receiving 750 mg daily in divided doses. 18 Even if all this penicillamine were free (i.e., unbound), this still represents less than 10% of the total serum SH level. However, at least 80% of penicillamine is bound to albumin through the SH group.'9 The finding of depressed SH levels before clinical relapse is apparent suggests that the mechanism responsible is already well established in these Thirdly, we found that reintroduction of penicillamine after it had been reduced or withdrawn was successful. Not all patients responded to the same dose of penicillamine, but all patients regained a complete clinical remission, although the CRP had not returned to normal in 5 patients. In this respect penicillamine is different from gold, where reintroduction of gold therapy after withdrawal or previous courses is less successful.2" These differences, however, are probably explained by selection of patients and differences in design study. Our patients were selected because they were in remission for at least 18 months (12 months retrospectively and 6 months prospectively) and had done extremely well on the drug.
The study suggests that indefinite treatment with penicillamine, provided no toxicity occurs, is advisable. 20% of the patients attempting penicillamine withdrawal remained in remission 9-12 months after stopping penicillamine but 80% flared, of whom two-thirds had polyarticular synovitis and asked to resume their former therapy. We do not believe that the benefits profiting the minority justify putting the majority at risk of developing a severe flare. However, we realise that this is contentious, as penicillamine therapy must be continually monitored, creating inconvenience and utilisation of time and resources for patients and medical staff. It remains possible that a slower reduction schedule (e.g., over 3 years or 125 mg every 3 months) might be successful. 
